0.00Open0.00Pre Close0 Volume0 Open Interest25.00Strike Price0.00Turnover0.00%IV40.13%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma89.20Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet